Zimelidine: a therapeutic and pharmacokinetic study in depression.
Zimelidine, a bicyclic compound with a strong effect on the neuronal reuptake of 5-hydroxy-tryptamine and with weak anticholinergic actions, was evaluated for its antidepressant efficacy in a double-blind comparative trial with amitriptyline. In doses of 200 mg a day it was found to be as effective as 150 mg amitriptyline, but with significantly less subjective side-effects. The plasma concentration of zimelidine and its metabolite, norzimelidine, showed no significant correlation with therapeutic outcome.
D000499:Allylamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001835:Body Weight; D001643:Bridged Bicyclo Compounds / Q000009:adverse effects; D003863:Depression / Q000188:drug therapy*; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011725:Pyridines / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D000928:Antidepressive Agents; D001643:Bridged Bicyclo Compounds; D011725:Pyridines; D000639:Amitriptyline; D000499:Allylamine